Related Experiment Video

Updated: Mar 7, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

17.1K

SiRNA-based inactivation of Angptl3 alleviates high-fat diet-induced MAFLD and atherosclerosis in LDLR-deficient

Xiaohong Zhang1, Yufei Han2, Liwen Zheng2

  • 1Clinical Laboratory Department, Beijing Tongren Hospital, Capital Medical University, Beijing, China.

Lipids in Health and Disease
|March 5, 2026
PubMed
Abstract

No abstract available in PubMed .

Keywords:
Angiopoietin-like protein 3AtherosclerosisLow-density lipoprotein receptorMetabolic dysfunction-associated fatty liver diseaseSmall interfering RNA

More Related Videos

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

1.0K
Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells09:15

Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells

Published on: July 18, 2019

9.6K

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
538